Ionosol And Dextrose
Loading...Ionosol And Dextrose Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.
Solutions containing lactate ions should be used with great care, if at all, in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of lactate ions, such as severe hepatic insufficiency.
The intravenous administration of Ionosol B and 5% Dextrose Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Ionosol B and 5% Dextrose Injection is indicated for intravenous administration to patients who require a maintenance source of fluid and electrolytes.
Ionosol B and 5% Dextrose Injection is used in patients requiring polyionic fluid maintenance, for alkalosis due to vomiting, diabetic acidosis, fluid losses due to burns or stress and postoperative dehydration.
History
There is currently no drug history available for this drug.
Other Information
Ionosol B and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is a sterile, nonpyrogenic solution designed for intravenous administration. The solution is formulated to meet maintenance requirements for fluid and electrolytes.
Each 100 mL contains dextrose, hydrous 5 g plus sodium chloride 180 mg; potassium chloride 100 mg; sodium lactate, anhydrous 280 mg; magnesium chloride, hexahydrate 53 mg; dibasic potassium phosphate, anhydrous 100 mg; and monobasic sodium phosphate, monohydrate 16 mg.
Each liter contains 57 mEq sodium (Na+); 25 mEq potassium (K+); 5 mEq magnesium (Mg++); 49 mEq chloride (Cl−); 7 mM phosphate (PO4≡); and 25 mEq lactate (CH3CH(OH)COO–).
The electrolyte content is hypotonic (174 mOsmol/L, calc.) in relation to the extracellular fluid (approx. 280 mOsmol/L). The osmolarity for the total solution is 426 mOsmol/L (calc.). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. pH is 5.0 (4.0 to 6.5).
Dextrose, USP, hydrous is chemically designated C6H12O6 • H2O (D-glucose, monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following structural formula:
structural formula dextrose
Magnesium Chloride, USP, hexahydrate is chemically designated MgCl2 • 6H2O, colorless flakes or crystals very soluble in water.
Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.
Dibasic Potassium Phosphate, USP, anhydrous is chemically designated K2HPO4, white granules very soluble in water.
Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.
Sodium Lactate, USP is chemically designated CH3CH(OH)COONa, a 60% aqueous solution miscible in water.
Monobasic Sodium Phosphate, USP, monohydrate is chemically designated NaH2PO4 • H2O, white crystals or granules freely soluble in water.
Water for Injection, USP is chemically designated H2O.
The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of their chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.
Sources
Ionosol And Dextrose Manufacturers
-
Hospira, Inc.
![Ionosol And Dextrose (Dextrose Monohydrate, Sodium Chloride, Potassium Chloride, Sodium Lactate, Magnesium Chloride, Potassium Phosphate, Dibasic, And Sodium Phosphate, Monobasic, Monohydrate) Injection, Solution [Hospira, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ionosol And Dextrose | Hospira, Inc.
The dose is dependent upon the age, weight and clinical condition of the patient. The nominal dosage level for adults is 30 mL/kg. Ionosol B and 5% Dextrose Injection is administered intravenously.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. (See PRECAUTIONS.)
INSTRUCTIONS FOR USE
To Open:
Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
If supplemental medication is desired, follow directions below before preparing for administration.
To Add Medication
1. Prepare additive port.
2. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.
3. The additive port may be protected by covering with an additive cap.
4. Mix container contents thoroughly.
To Administer
1. Attach administration set per manufacturer’s instructions.
2. Regulate rate of administration per institutional policy.
WARNING: Do not use flexible container in series connections.
-
Hospira, Inc.
Ionosol And Dextrose | Hospira, Inc.
The dose is dependent upon the age, weight and clinical condition of the patient.
In infants, Ionosol MB and 5% Dextrose Injection is given only after administration of an initial priming solution: 15 mL of half isotonic saline in 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight, administered to small infants at a maximum rate of 0.8 mL/minute. Infants typically tolerate not more than 150 to 200 mL of Ionosol MB and 5% Dextrose Injection per kg body weight/day.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
In adults, intravenous infusions of Ionosol MB and 5% Dextrose Injection are given postoperatively, at a rate not greater than 4 mL/minute.
Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. See PRECAUTIONS.
INSTRUCTIONS FOR USE
To Open:
Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
If supplemental medication is desired, follow directions below before preparing for administration.
To Add Medication
Prepare additive port.
Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.
The additive port may be protected by covering with an additive cap.
Mix container contents thoroughly.
To Administer
Attach administration set per manufacturer’s instructions.
Regulate rate of administration per institutional policy.
WARNING: Do not use flexible container in series connections.
![Ionosol And Dextrose (Dextrose Monohydrate, Sodium Lactate, Potassium Chloride, Magnesium Chloride, Potassium Phosphate, Monobasic, And Sodium Phosphate, Monobasic, Monohydrate) Injection, Solution [Hospira, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=207aab2b-4be1-4629-ffb5-5481e2ad534f&name=ionosol-mb-and-5prct-dextrose-injection2-figure-2-jIM-0469.jpg)
Login To Your Free Account